Table 4.
Deleterious mutations found in actionable genes
| Gene | Drugs in relation with gene of interest | Mutation | Number of tumors | Transcript | Associated clinical trial |
|---|---|---|---|---|---|
| ALK | Crizotinib, Ceritinib | A1266TA1234VV1149LR1120Q | 4 | NM_004304 | NCT01548144, NCT01744652 |
| AR | Entuzalamide, Abiraterone | K809N | 1 | NM_000044 | – |
| EGFR | Cetuximab, Panitumumab, Erlotinib, Gefetinib, Afatinib, Vandetanib | S511YT259MA611T | 3 | NM_005228 | NCT00770263 |
| ERBB2 | Trastuzumab, Pertuzumab, Lapatinib | L696F | 1 | NM_001005862 | NCT01953926 |
| KRAS | Resistance to Cetuximab and others | G12DG13D | 4 | NM_033360 | – |
| MET | Cabozantinib | L342F | 1 | NM_001127500 | – |
| mTOR | Temsirolimus, Everolimus | M813I | 1 | NM_004958 | – |
| PDGFRA | Regorafenib | P441L | 1 | NM_006206 | NCT02029001 |
| RAF1 | Regorafenib | C96FQ255H | 2 | NM_002880 | – |
Genes are linked to targeted therapies already approved by Food and Drug Administration in at least one indication. All potential drug targets of each therapy are considered.